Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · Real-Time Price · USD
8.67
-0.08 (-0.91%)
At close: Jan 21, 2026, 4:00 PM EST
8.84
+0.17 (1.96%)
Pre-market: Jan 22, 2026, 8:48 AM EST
Tilray Brands Revenue
Tilray Brands had revenue of $217.51M in the quarter ending November 30, 2025, with 3.11% growth. This brings the company's revenue in the last twelve months to $837.32M, up 0.98% year-over-year. In the fiscal year ending May 31, 2025, Tilray Brands had annual revenue of $821.31M with 4.10% growth.
Revenue (ttm)
$837.32M
Revenue Growth
+0.98%
P/S Ratio
1.05
Revenue / Employee
$294,625
Employees
2,842
Market Cap
1.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 821.31M | 32.37M | 4.10% |
| May 31, 2024 | 788.94M | 161.82M | 25.80% |
| May 31, 2023 | 627.12M | -1.25M | -0.20% |
| May 31, 2022 | 628.37M | 115.29M | 22.47% |
| May 31, 2021 | 513.09M | 302.60M | 143.77% |
| Dec 31, 2020 | 210.48M | -194.84M | -48.07% |
| May 31, 2020 | 405.33M | 27.87M | 7.38% |
| Dec 31, 2019 | 377.46M | 198.16M | 110.52% |
| Jun 30, 2019 | 179.30M | 136.17M | 315.73% |
| Dec 31, 2018 | 43.13M | - | - |
| Jun 30, 2018 | 43.13M | 22.59M | 110.00% |
| Dec 31, 2017 | 20.54M | - | - |
| Jun 30, 2017 | 20.54M | 7.89M | 62.43% |
| Dec 31, 2016 | 12.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Collegium Pharmaceutical | 757.07M |
| Amphastar Pharmaceuticals | 723.31M |
| Pacira BioSciences | 716.79M |
| BioCryst Pharmaceuticals | 599.82M |
| Alvotech | 573.35M |
| Ironwood Pharmaceuticals | 338.99M |
| Esperion Therapeutics | 303.80M |
TLRY News
- 1 hour ago - SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer - GlobeNewsWire
- 2 hours ago - Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio - GlobeNewsWire
- 5 days ago - 3 Canadian Marijuana Stocks For Investors In 2026 - MarijuanaStocks
- 12 days ago - International Cannabis Expansion Gives Tilray Positive 2026 Outlook - Seeking Alpha
- 13 days ago - Marijuana industry taking fight against Wall Street blockades straight to Trump - New York Post
- 13 days ago - Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Tilray Stock Fires Up After Record Q2 Earnings: Here's Why - Benzinga
- 13 days ago - Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance - GlobeNewsWire